Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Caribou Biosciences, Inc. (CRBU)

9.14   -0.47 (-4.89%) 12-05 16:00
Open: 9.5 Pre. Close: 9.61
High: 9.505 Low: 9.01
Volume: 428,737 Market Cap: 558(M)

Technical analysis

as of: 2022-12-06 8:17:08 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 11.41     One year: 12.46
Support: Support1: 8.31    Support2: 6.92
Resistance: Resistance1: 9.77    Resistance2: 10.67
Pivot: 9.13
Moving Average: MA(5): 9.11     MA(20): 9.25
MA(100): 9.65     MA(250): 9.56
MACD: MACD(12,26): -0.2     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 41.8     %D(3): 37.4
RSI: RSI(14): 47.9
52-week: High: 18.26  Low: 4.88
Average Vol(K): 3-Month: 653 (K)  10-Days: 422 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CRBU ] has closed below upper band by 49.7%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.53 - 9.57 9.57 - 9.61
Low: 8.88 - 8.95 8.95 - 9
Close: 9.05 - 9.15 9.15 - 9.22

Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Headline News

Thu, 01 Dec 2022
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector - Baystreet.ca

Tue, 29 Nov 2022
CRBU stock gains on FDA designations for cell therapy candidate (NASDAQ:CRBU) - Seeking Alpha

Sat, 12 Nov 2022
Positive week for Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional investors who lost 52% over the past year - Simply Wall St

Wed, 09 Nov 2022
Is Caribou Biosciences Inc (CRBU) a Leader in the Biotechnology Industry? - InvestorsObserver

Wed, 09 Nov 2022
Growth Investors: Industry Analysts Just Upgraded Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts By 27% - Yahoo Finance

Fri, 04 Nov 2022
Caribou Biosciences, Inc. (CRBU) Stock Price Today, Quote & News - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 43 (M)
% Held by Insiders 10.7 (%)
% Held by Institutions 72 (%)
Shares Short 3,620 (K)
Shares Short P.Month 4,030 (K)

Stock Financials

EPS -1.64
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.3
Profit Margin (%) 0
Operating Margin (%) -756.7
Return on Assets (ttm) -14
Return on Equity (ttm) -25
Qtrly Rev. Growth -16.9
Gross Profit (p.s.) -0.7
Sales Per Share 0.2
EBITDA (p.s.) -1.56
Qtrly Earnings Growth 0
Operating Cash Flow -87 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -5.58
PEG Ratio 0.5
Price to Book value 1.72
Price to Sales 43.83
Price to Cash Flow -6.39

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.